Drugs that contain Ferric Carboxymaltose

1. Drug name - INJECTAFER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11123321 AM REGENT Aqueous iron carbohydrate complexes, their production and medicaments containing them
Oct, 2023

(1 year, 20 days from now)

US9376505 AM REGENT Aqueous iron carbohydrate complexes, their production and medicaments containing them
Oct, 2023

(1 year, 20 days from now)

US7612109 AM REGENT Water-soluble iron-carbohydrate complexes, production thereof, and medicaments containing said complexes
Feb, 2024

(1 year, 4 months from now)

CN100480275C AM REGENT Water Soluble Iron Carbohydrate Complex, Its Preparation And Medicine Containing The Same
Oct, 2023

(1 year, 20 days from now)

CN1705682A AM REGENT Water Soluble Iron Carbohydrate Complex, Its Preparation And Medicine Containing The Same
Oct, 2023

(1 year, 20 days from now)

IN221536B AM REGENT Water Soluble Iron Carbohydrate Comples And A Process For Producing Water Soluble Iron Carboyydrate Complex
Oct, 2023

(1 year, 20 days from now)

IN200500947P2 AM REGENT Water Soluble Iron Carbohydrate Comples And A Process For Producing Water Soluble Iron Carboyydrate Comoplex
Oct, 2023

(1 year, 20 days from now)

EP1554315B1 AM REGENT Water-Soluble Iron-Carbohydrate Complexes, Production Thereof, And Medicaments Containing Said Complexes
Oct, 2023

(1 year, 20 days from now)

EP1554315A1 AM REGENT Water-Soluble Iron-Carbohydrate Complexes, Production Thereof, And Medicaments Containing Said Complexes
Oct, 2023

(1 year, 20 days from now)

EP2287204A1 AM REGENT Water-Soluble Iron-Carbohydrate Complexes, Production Thereof, And Medicaments Containing Said Complexes
Oct, 2023

(1 year, 20 days from now)

EP2287204B1 AM REGENT Water-Soluble Iron-Carbohydrate Complexes, Production Thereof, And Medicaments Containing Said Complexes
Oct, 2023

(1 year, 20 days from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8895612 AM REGENT Methods and compositions for administration of iron Jan, 2027

(4 years from now)

US7754702 AM REGENT Methods and compositions for administration of iron Feb, 2028

(5 years from now)

Treatment: Method of treatment of iron-related conditions with at least 0.6 grams of elemental iron via an iron carbohydrate complex, with a substantially non-immunogenic carbohydrate component, in about 15 minutes or less.; method of treating iron deficiency anemia in adult patients who have non-dialysis dependent chronic kidney disease by intravenously administering at least about 0.6g of iron as ferric carboxymaltose in about 15 min or less; method of treating iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron by intravenously administering at least about 0.6g of iron as ferric carboxymaltose in about 15 min or less; method of treating iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron by intravenously administering about 1 g of iron as ferric carboxymaltose in about 15 minutes or less; method of treating iron deficiency anemia in adult patients who have non-dialysis dependent chronic kidney disease by intravenously administering about 1 g of iron as ferric carboxymaltose in about 15 minutes or less; method to treat ida in adults & pediatric patients 1 yr & older with intolerance or unsatisfactory response to oral iron & weighing at least 40 kg by administering iv at least about 0.6 g of iron as ferric carboxymaltose in about 15 min or less; method of treating ida in adult patients with non-dialysis dependent chronic kidney disease & weighing at least 40 kg by intravenously administering at least about 0.6 grams of iron as ferric carboxymaltose in about 15 minutes or less; Method of treatment of iron-related conditions with at least 0.6 grams of elemental iron via an iron carbohydrate complex; method of treating iron deficiency anemia in adults who have intolerance to or have had unsatisfactory response to oral iron associated with heavy uterine bleeding or a gastrointestinal disorder by intravenously administering ferric carboxymaltose; a method of treating iron deficiency anemia in adult patients who have non-dialysis dependent chronic kidney disease by intravenously administering ferric carboxymaltose to provide at least about 0.6 grams of elemental iron; a method of treating iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron by intravenously administering ferric carboxymaltose to provide at least about 0.6 g of elemental iron; method to treat ida in adults & pediatric patients 1 yr & older with intolerance or unsatisfactory response to oral iron & weighing at least 40 kg by intravenously administering ferric carboxymaltose to provide at least about 0.6 g of elemental iron; method of treating ida in adults & pediatric patients 1 yr & older having intolerance or unsatisfactory response to oral iron associated with heavy uterine bleeding or gastrointestinal disorder by intravenously administering ferric carboxymaltose; method of treating ida in adult patients with non-dialysis dependent chronic kidney disease & weighing at least 40 kg by intravenously administering ferric carboxymaltose to provide at least about 0.6 grams of elemental iron

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
1GM IRON/20ML (50MG IRON/ML) SOLUTION;INTRAVENOUS Prescription
750MG IRON/15ML (50MG IRON/ML) SOLUTION;INTRAVENOUS Prescription
100MG IRON/2ML (50MG IRON/ML) SOLUTION;INTRAVENOUS Prescription
500MG IRON/10ML (50MG IRON/ML) SOLUTION;INTRAVENOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.